Top Markets
Coin of the day
Eli Lilly Eli Lilly

Eli Lilly

LLY
Rang in Aktien #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Aktienkurs
$910.55
Marktkapitalisierung
$860.30B
Veränderung (1 Tag)
0.44%
Veränderung (1 Jahr)
5.28%
Land
US
Handel Eli Lilly (LLY)

Kategorie

Gewinn für Eli Lilly (LLY)
Gewinn im Dec 2025 TTM: $25.73B
Laut den aktuellen Finanzberichten von Eli Lilly betragen die aktuellen Gewinne des Unternehmens $25.73B. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $12.68B, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $6.55B betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Eli Lilly von 2000 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $25.73B 0.00%
2025 $25.73B 102.91%
2024 $12.68B 93.46%
2023 $6.55B -3.70%
2022 $6.81B 10.57%
2021 $6.16B -14.86%
2020 $7.23B 37.30%
2019 $5.27B 43.09%
2018 $3.68B 59.67%
2017 $2.30B -31.69%
2016 $3.37B 20.93%
2015 $2.79B -7.01%
2014 $3.00B -49.06%
2013 $5.89B 8.90%
2012 $5.41B 1.10%
2011 $5.35B -18.02%
2010 $6.53B 21.79%
2009 $5.36B -509.74%
2008 $-1.31B -133.73%
2007 $3.88B 13.42%
2006 $3.42B 25.78%
2005 $2.72B -7.63%
2004 $2.94B -9.80%
2003 $3.26B -5.67%
2002 $3.46B -2.66%
2001 $3.55B -7.95%
2000 $3.86B 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
$12.40B -51.80%
GB
$32.58B 26.63%
US
$6.60B -74.36%
US
$16.35B -36.45%
CH
$21.07B -18.12%
US